Poster – Assessing Clinical Response in Multiple Myeloma Patients Treated with Monoclonal Antibodies
Reach out to our experts and discover how we can help advance your researchContact Us
In light of the global COVID-19 (SARS-Cov-2) pandemic, the search for a treatment or vaccine has become urgent and critical. Cerba Research, together with all its partners, is widely using COVID-19 diagnostic tests to detect the virus in patients. In addition, we are assisting in making testing available in clinical trials globally.
Please, feel free to reach out to us if our COVID-19 capabilities and overall understanding of coronavirus pathogenesis can help advance the development of your treatment.
We have central laboratories in USA, Europe, Asia Pacific, China and Australia. This means you can count on Cerba Research to ensure that study setup, site preparation and sample collection, through to delivery and results reporting via our single global database enables the end-point reporting you need to keep your clinical trial on track.
Our Histoprofile®- T-reg light panel is ready for use in your clinical trials
Accurate characterization of the tumor micro-environment when tissue sample access is limited can be an important challenge in the field of immuno-oncology. The balance and tumor infiltration of T cell subpopulations are of particular interest and its importance has been repeatedly demonstrated in the literature. T cells are important immune effector cells and are therefore preferred targets for immuno-modulation.
Conventional T cells can be broadly classified as helper (Th), cytotoxic (Tcyto), memory or regulatory (Treg) cells. Tcyto cells ensure optimal immune responses against invading microbes and tumor antigens. Under homeostatic conditions, Tregs promote peripheral tolerance. However, within tumors, Tregs can supress Tcyto cell functions. The multiplex protocol, Histoprofile®- T-reg light panel, developed at Cerba Research on the Discovery ULTRA (Ventana) platform is designed to stain specific sub-populations of T cells on a single slide, avoiding the need of serial sections from precious patient’s FFPE samples in clinical trials while still providing an indepth analysis of the tumor microenvironment.
Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues. Evaluate T-cell subpopulations and their spatial distribution in the tumor microenvironment.
Reach out to our experts and discover how we can help advance your clinical trialContact Us
Hematological malignancies originate from the uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers worldwide, and for approximately 9.5% of newly diagnosed cancers every year.
Due to the high level of heterogeneity in cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional, and metabolic alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes.
At Cerba Research, we aim to bring a multi-modal approach to precision medicine to disease. From discovery to clinical development, we provide world-class teams and capabilities worldwide to help you in your quest for novel treatment against hematological malignancies.
HISTOSELECT®: The number one solution for direct screening of large numbers of antibodies by immunohistochemistry (IHC).
Cerba Research offers in-house in situ biomarkers expertise managed by our research scientists, with over 200 optimized IHC and IF protocols, from simplex to multiplex solutions, to suit the needs of any project. The scientific-driven R&D team can provide complete IHC assay development/optimization or assay transfer of clients’ methods and the subsequent fit-for-purpose validation.
Biomarkers can triple drug development success rates when used in clinical research. While scientific and technological advances have led to the discovery of more circulating biomarker candidates, the challenge lies in validating those biomarkers.
Cerba Research takes a personalized approach to biomarker assay development and validation to help clients improve their odds of success. This approach involves the experience of our leading scientists, and our five-continent laboratory network.
Our highly specialized custom assays, innovative anatomical pathology biomarker support, and biomarker strategies de-risk study conduct and generate the data you need to bring new therapies to light. From translational research to clinical through commercialization, Cerba actuates real-world data to help you reach patients and bring clarity to complex research.
Cerba Research provides flexible, tailored biomarker solutions through a network of labs across five continents. When you partner with us, you gain the operational and scientific expertise to advance targeted approaches and broad immune profiling. Together, we will develop biomarker strategies that help your trial succeed.
But which biomarkers can Cerba Research test on? Discover it here in this downloadable brochure.
Discover the art of histopathology through the eyes of our most skilled scientists.
Immunohistochemistry biomarkers are key players in clinical development success. Tissue biomarkers can aid in the confirmation of diagnosis, patient selection, and/or for mechanistic evaluation.
If you would like to know more about how Cerba Research can help you, our IHC expert scientific team will consult with you on your specific needs. Flexible in our approach and delivery to provide timely and cost effective solutions to meet your clinical and commercial objectives.
Download our digital book to see the art of histopathology for yourself.
Reach out to our experts and see how we can help advance your clinical trialContact Us
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.
In this webinar our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.
Reach out to our experts to see how we can help advance your clinical trialContact Us